BTKi discontinuation in CLL: intolerance & disease progression
1 year ago
[{"url":"https://i.ytimg.com/vi/pPcEHzJ6gs0/hq720.jpg?sqp=-oaymwEcCOgCEMoBSFXyq4qpAw4IARUAAIhCGAFwAcABBg==&rs=AOn4CLBNvyJQepO_PM1LVPi8AAxMBNuYPQ","width":360,"height":202},{"url":"https://i.ytimg.com/vi/pPcEHzJ6gs0/hq720.jpg?sqp=-oaymwEcCNAFEJQDSFXyq4qpAw4IARUAAIhCGAFwAcABBg==&rs=AOn4CLALFMj6qGlDuMp0i23GFHs1aAZLZw","width":720,"height":404}]
{"url":"https://i.ytimg.com/an_webp/pPcEHzJ6gs0/mqdefault_6s.webp?du=3000&sqp=CPnNsKkG&rs=AOn4CLC6CkO9ZHOOG3D17JaMrJdc-IFj2A","width":320,"height":180}
[{"text":"Neil Kay, MD, Mayo Clinic, Rochester, MN, talks on discontinuation of Bruton's tyrosine kinase inhibitors (BTKi) for "},{"text":"intolerance","bold":true},{"text":" and\u00a0..."}]
{"name":"VJHemOnc \u2013 Video Journal of Hematological Oncology","id":"UCsQXL4_zTA-FoG9RA1tEGiw","thumbnails":[{"url":"https://yt3.ggpht.com/tLfkaYbACnFuAto-jU_XMyorvysy280aW3Kj1oDAKOH7nd58XYlz5rEL24x9ScNjruMr2YYw9w=s68-c-k-c0x00ffffff-no-rj","width":68,"height":68}],"link":"https://www.youtube.com/channel/UCsQXL4_zTA-FoG9RA1tEGiw"}
{"title":"BTKi discontinuation in CLL: intolerance & disease progression by VJHemOnc \u2013 Video Journal of Hematological Oncology 143 views 1 year ago 2 minutes, 13 seconds","duration":"2 minutes, 13 seconds"}